Vaxcyte Stock Based Compensation vs End Period Cash Flow Analysis

PCVX Stock

USD 94.34 0.36 0.38%

Vaxcyte financial indicator trend analysis is much more than just breaking down Vaxcyte prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Vaxcyte is a good investment. Please check the relationship between Vaxcyte Stock Based Compensation and its End Period Cash Flow accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Vaxcyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For more information on how to buy Vaxcyte Stock please use our How to Invest in Vaxcyte guide.

Stock Based Compensation vs End Period Cash Flow

Stock Based Compensation vs End Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Vaxcyte Stock Based Compensation account and End Period Cash Flow. At this time, the significance of the direction appears to have strong relationship.

The correlation between Vaxcyte's Stock Based Compensation and End Period Cash Flow is 0.62. Overlapping area represents the amount of variation of Stock Based Compensation that can explain the historical movement of End Period Cash Flow in the same time period over historical financial statements of Vaxcyte, assuming nothing else is changed. The correlation between historical values of Vaxcyte's Stock Based Compensation and End Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Stock Based Compensation of Vaxcyte are associated (or correlated) with its End Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when End Period Cash Flow has no effect on the direction of Stock Based Compensation i.e., Vaxcyte's Stock Based Compensation and End Period Cash Flow go up and down completely randomly.

Correlation Coefficient

0.62

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

End Period Cash Flow

Most indicators from Vaxcyte's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Vaxcyte current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Vaxcyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For more information on how to buy Vaxcyte Stock please use our How to Invest in Vaxcyte guide.Selling General Administrative is likely to rise to about 63.7 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 364.6 M in 2024.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	1.8M	9.2M	3.2M	4.0M
Net Interest Income	337K	8.4M	62.9M	66.1M

Depreciation And Amortization Net Interest Income

Vaxcyte fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Other Assets	Long Term Debt	Cash And Short Term Investments	Common Stock Shares Outstanding	Long Term Debt Total	Capital Surpluse	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Short Long Term Debt Total	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Non Current Assets Total	Non Currrent Assets Other	Common Stock Total Equity
Total Assets		0.92	0.95	0.99	-0.94	0.99	-0.99	0.54	0.73	0.2	-0.73	0.99	0.86	-0.73	0.88	0.52	1.0	0.96	0.87	0.85	0.94	-0.67	-0.76	0.93	0.91	0.76
Other Current Liab	0.92		0.99	0.9	-0.79	0.87	-0.94	0.45	0.44	-0.12	-0.6	0.88	0.78	-0.6	0.74	0.58	0.88	0.84	0.76	0.73	0.98	-0.53	-0.48	0.99	0.99	0.58
Total Current Liabilities	0.95	0.99		0.93	-0.85	0.91	-0.96	0.56	0.53	-0.04	-0.68	0.92	0.82	-0.68	0.83	0.56	0.92	0.9	0.79	0.8	0.97	-0.61	-0.56	0.97	0.97	0.68
Total Stockholder Equity	0.99	0.9	0.93		-0.96	1.0	-0.98	0.54	0.75	0.23	-0.69	0.99	0.84	-0.69	0.89	0.42	0.99	0.97	0.88	0.86	0.92	-0.64	-0.78	0.91	0.89	0.77
Other Liab	-0.94	-0.79	-0.85	-0.96		-0.97	0.93	-0.6	-0.81	-0.44	0.74	-0.96	-0.84	0.74	-0.95	-0.36	-0.96	-0.98	-0.92	-0.92	-0.84	0.7	0.82	-0.81	-0.77	-0.88
Net Tangible Assets	0.99	0.87	0.91	1.0	-0.97		-0.97	0.57	0.8	0.3	-0.74	1.0	0.86	-0.74	0.91	0.44	1.0	0.98	0.89	0.88	0.9	-0.69	-0.82	0.88	0.85	0.81
Retained Earnings	-0.99	-0.94	-0.96	-0.98	0.93	-0.97		-0.51	-0.66	-0.19	0.75	-0.97	-0.89	0.75	-0.88	-0.57	-0.97	-0.96	-0.9	-0.86	-0.97	0.69	0.68	-0.95	-0.93	-0.76
Accounts Payable	0.54	0.45	0.56	0.54	-0.6	0.57	-0.51		0.62	0.11	-0.7	0.57	0.63	-0.7	0.74	0.3	0.57	0.66	0.36	0.72	0.37	-0.69	-0.61	0.37	0.36	0.77
Cash	0.73	0.44	0.53	0.75	-0.81	0.8	-0.66	0.62		0.53	-0.67	0.8	0.71	-0.67	0.74	0.3	0.8	0.77	0.61	0.72	0.46	-0.67	-0.99	0.43	0.39	0.76
Other Assets	0.2	-0.12	-0.04	0.23	-0.44	0.3	-0.19	0.11	0.53		-0.46	0.26	0.31	-0.46	0.45	-0.02	0.26	0.37	0.53	0.37	0.04	-0.5	-0.48	-0.04	-0.12	0.55
Long Term Debt	-0.73	-0.6	-0.68	-0.69	0.74	-0.74	0.75	-0.7	-0.67	-0.46		-0.74	-0.86	1.0	-0.86	-0.63	-0.75	-0.83	-0.74	-0.75	-0.62	1.0	0.65	-0.59	-0.55	-0.84
Cash And Short Term Investments	0.99	0.88	0.92	0.99	-0.96	1.0	-0.97	0.57	0.8	0.26	-0.74		0.87	-0.74	0.89	0.5	1.0	0.97	0.86	0.85	0.9	-0.69	-0.82	0.88	0.86	0.78
Common Stock Shares Outstanding	0.86	0.78	0.82	0.84	-0.84	0.86	-0.89	0.63	0.71	0.31	-0.86	0.87		-0.86	0.86	0.67	0.87	0.89	0.81	0.91	0.79	-0.84	-0.68	0.77	0.74	0.87
Long Term Debt Total	-0.73	-0.6	-0.68	-0.69	0.74	-0.74	0.75	-0.7	-0.67	-0.46	1.0	-0.74	-0.86		-0.86	-0.63	-0.75	-0.83	-0.74	-0.75	-0.62	1.0	0.65	-0.59	-0.55	-0.84
Capital Surpluse	0.88	0.74	0.83	0.89	-0.95	0.91	-0.88	0.74	0.74	0.45	-0.86	0.89	0.86	-0.86		0.4	0.89	0.97	0.89	0.93	0.79	-0.84	-0.74	0.75	0.71	0.95
Total Liab	0.52	0.58	0.56	0.42	-0.36	0.44	-0.57	0.3	0.3	-0.02	-0.63	0.5	0.67	-0.63	0.4		0.5	0.46	0.41	0.41	0.53	-0.6	-0.26	0.54	0.54	0.37
Total Current Assets	1.0	0.88	0.92	0.99	-0.96	1.0	-0.97	0.57	0.8	0.26	-0.75	1.0	0.87	-0.75	0.89	0.5		0.97	0.87	0.86	0.9	-0.7	-0.82	0.88	0.86	0.78
Common Stock	0.96	0.84	0.9	0.97	-0.98	0.98	-0.96	0.66	0.77	0.37	-0.83	0.97	0.89	-0.83	0.97	0.46	0.97		0.91	0.92	0.88	-0.79	-0.78	0.85	0.82	0.89
Property Plant Equipment	0.87	0.76	0.79	0.88	-0.92	0.89	-0.9	0.36	0.61	0.53	-0.74	0.86	0.81	-0.74	0.89	0.41	0.87	0.91		0.83	0.87	-0.71	-0.61	0.82	0.77	0.8
Short Long Term Debt Total	0.85	0.73	0.8	0.86	-0.92	0.88	-0.86	0.72	0.72	0.37	-0.75	0.85	0.91	-0.75	0.93	0.41	0.86	0.92	0.83		0.77	-0.72	-0.7	0.74	0.71	0.96
Property Plant And Equipment Net	0.94	0.98	0.97	0.92	-0.84	0.9	-0.97	0.37	0.46	0.04	-0.62	0.9	0.79	-0.62	0.79	0.53	0.9	0.88	0.87	0.77		-0.55	-0.49	1.0	0.99	0.63
Current Deferred Revenue	-0.67	-0.53	-0.61	-0.64	0.7	-0.69	0.69	-0.69	-0.67	-0.5	1.0	-0.69	-0.84	1.0	-0.84	-0.6	-0.7	-0.79	-0.71	-0.72	-0.55		0.64	-0.52	-0.47	-0.84
Net Debt	-0.76	-0.48	-0.56	-0.78	0.82	-0.82	0.68	-0.61	-0.99	-0.48	0.65	-0.82	-0.68	0.65	-0.74	-0.26	-0.82	-0.78	-0.61	-0.7	-0.49	0.64		-0.46	-0.43	-0.73
Non Current Assets Total	0.93	0.99	0.97	0.91	-0.81	0.88	-0.95	0.37	0.43	-0.04	-0.59	0.88	0.77	-0.59	0.75	0.54	0.88	0.85	0.82	0.74	1.0	-0.52	-0.46		1.0	0.59
Non Currrent Assets Other	0.91	0.99	0.97	0.89	-0.77	0.85	-0.93	0.36	0.39	-0.12	-0.55	0.86	0.74	-0.55	0.71	0.54	0.86	0.82	0.77	0.71	0.99	-0.47	-0.43	1.0		0.54
Common Stock Total Equity	0.76	0.58	0.68	0.77	-0.88	0.81	-0.76	0.77	0.76	0.55	-0.84	0.78	0.87	-0.84	0.95	0.37	0.78	0.89	0.8	0.96	0.63	-0.84	-0.73	0.59	0.54

Click cells to compare fundamentals

Vaxcyte Account Relationship Matchups

Vaxcyte fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	65.7M	392.8M	324.3M	1.0B	1.4B	1.5B
Other Current Liab	7.5M	17.1M	11.4M	18.9M	116.5M	122.4M
Total Current Liabilities	11.1M	46.9M	28.7M	40.5M	145.3M	152.6M
Total Stockholder Equity	(106.4M)	345.8M	284.0M	953.6M	1.2B	1.3B
Other Liab	259K	122K	96K	9K	8.1K	7.7K
Net Tangible Assets	(106.4M)	345.8M	284.0M	953.6M	1.1B	1.2B
Retained Earnings	(109.3M)	(198.6M)	(298.6M)	(522.1M)	(924.4M)	(878.2M)
Accounts Payable	3.4M	29.8M	6.8M	9.8M	14.6M	10.8M
Cash	59.0M	386.2M	69.0M	834.7M	397.5M	290.5M
Other Assets	584K	550K	5.0M	5.4M	1.0	0.95
Cash And Short Term Investments	59.0M	386.2M	246.0M	931.4M	1.1B	1.1B
Common Stock Shares Outstanding	48.9M	51.1M	51.9M	64.9M	97.2M	57.4M
Capital Surpluse	1.3M	3.0M	544.4M	582.8M	670.3M	703.8M
Total Liab	172.1M	47.0M	40.3M	52.6M	167.4M	96.9M
Total Current Assets	61.7M	389.0M	256.3M	942.6M	1.1B	1.2B
Common Stock	7K	54K	56K	82K	98K	102.9K
Property Plant Equipment	3.4M	3.3M	35.9M	31.6M	36.4M	38.2M
Property Plant And Equipment Net	3.4M	3.3M	35.9M	31.6M	110.6M	116.2M
Net Debt	(58.8M)	(386.2M)	(52.2M)	(816.7M)	(368.2M)	(386.6M)
Non Current Assets Total	4.0M	3.8M	68.0M	63.6M	312.0M	327.6M
Non Currrent Assets Other	584K	550K	5.0M	5.4M	38.7M	40.6M
Liabilities And Stockholders Equity	65.7M	392.8M	324.3M	1.0B	1.4B	1.5B
Non Current Liabilities Total	161.0M	122K	11.6M	12.0M	22.1M	43.8M
Capital Lease Obligations	161K	0.0	16.8M	17.9M	29.2M	30.7M
Other Current Assets	2.7M	2.5M	9.2M	5.3M	15.7M	16.5M
Other Stockholder Equity	3.0M	151.5M	582.8M	1.5B	2.2B	2.3B
Net Invested Capital	(106.4M)	345.8M	284.0M	953.6M	1.2B	1.3B
Accumulated Other Comprehensive Income	(160.3M)	(392.8M)	(241K)	(361K)	179K	188.0K
Capital Stock	7K	54K	56K	82K	98K	55.6K
Non Current Liabilities Other	242K	112K	96K	9K	8.1K	7.7K
Net Working Capital	50.7M	342.1M	227.6M	902.0M	950.6M	998.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Vaxcyte Stock Analysis

When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Vaxcyte Stock Based Compensation vs End Period Cash Flow Analysis

Stock Based Compensation vs End Period Cash Flow

Stock Based Compensation vs End Period Cash Flow Correlation Analysis

Correlation Coefficient

Stock Based Compensation

End Period Cash Flow

Vaxcyte fundamental ratios Correlations

Vaxcyte Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Vaxcyte fundamental ratios Accounts

Also Currently Popular

Additional Tools for Vaxcyte Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Net Tangible Assets	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Net Tangible Assets
Total Current Assets	+ 1.0	Net Tangible Assets
Long Term Debt Total	+ 1.0	Long Term Debt
Current Deferred Revenue	+ 1.0	Long Term Debt

Net Debt	- 0.99	Cash
Retained Earnings	- 0.99	Total Assets
Common Stock	- 0.98	Other Liab
Retained Earnings	- 0.98	Total Stockholder Equity
Property Plant And Equipment Net	- 0.97	Retained Earnings
Total Current Assets	- 0.97	Retained Earnings